Competitive: Hyper Recruitment Solutions (HRS): We are currently looking for an NGS Scientist to join an exciting Genomics CRO, as they build their new NGS team in Cambridge. As the /... Cambridgeshire

Notice NOT-OD-20-151 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-075 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-094 from the NIH Guide for Grants and Contracts

Notice NOT-RM-20-023 from the NIH Guide for Grants and Contracts

Notice NOT-RM-20-022 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-093 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-20-031 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) is soliciting applications for a Human Biospecimen and Data Repository for Biomarkers Research ("Biomarkers Repository") in Neurological Disorders. Collaborative teams combining expertise in neuroscience, biomarkers, biospecimen handling, and data management are encouraged. Experience in biomarker research, such as evaluation of batch effects, protocol development, and analyte quality control measures, is expected. Successful applications will include a detailed description of 1) Administrative Structure, 2) Research and Resource Plan, and 3) Data Management and Web-Based activities.

Notice NOT-OD-20-150 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-147 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-254 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Funding Opportunity PAR-20-255 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

MS in computer science, human-computer interaction, electrical engineering, bioinformatics, robotics or related field. 5+ years experience developing in C/C++.
From Facebook - Tue, 28 Jul 2020 06:16:57 GMT - View all Redmond, WA jobs

Adapts bioinformatics tools, visualization packages, and annotation resources for research projects to independently and accurately perform research analysis –…
From Medical College of Wisconsin - Tue, 28 Jul 2020 03:09:43 GMT - View all Milwaukee, WI jobs

Funding Opportunity RFA-AG-21-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions.

Funding Opportunity PAR-20-279 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.

Notice NOT-CA-20-092 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-072 from the NIH Guide for Grants and Contracts

Competitive + Benefits: Heptares Therapeutics Limited: Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group Cambridge, Cambridgeshire

The Role and opportunity Are you a Senior Scientist looking to make an impact and shape the direction of research within an innovative internationally recognised